Summary
Background: Advanced or metastatic gallbladder carcinoma is regarded not much sensitive to chemotherapy. Standard chemotherapy regimens have not been established up to now.
Patients: We report on 5 patients with advanced gallbladder carcinoma who received chemotherapy with gemcitabine.
Results: Of these 5 patients, 3 demonstrated a partial remission and stable disease was achieved in another patient. Only one patient had no benefit from treatment with gemcitabine.
Conclusion: We conclude that gemcitabine may be an effective drug in the palliative treatment of gallbladder cancer, and thus its efficiency warrants evaluation in further studies.
Chemotherapie mit Gemcitabine beim fortgeschrittenen Gallenblasenkarzinom
Hintergrund: Das Gallenblasenkarzinom wird in fortgeschrittenem Stadium als nur gering chemotherapiesensitiv angesehen. Standard-Chemotherapieprotokolle sind bisher nicht etabliert.
Patienten: Wir berichten über 5 Patienten, die eine Chemotherapie mit Gemcitabine erhielten.
Ergebnisse: Bei 3 von 5 Patienten zeigte sich unter Chemotherapie mit Gemcitabine eine partielle Remission, bei einem weiteren Patienten wurde ein stabiler Krankheitsverlauf erzielt. Nur ein Patient profitierte nicht von der Behandlung mit Gemcitabine.
Schlussfolgerung: Wir folgern daraus, dass Gemcitabine ein wirkungsvolles Medikament zur palliativen Behandlung des Gallenblasenkarzinoms sein kann. Die Effektivität von Gemcitabine beim fortgeschrittenen Gallenblasenkarzinom sollte in weiteren Studien untersucht werden.
Key words
Gallbladder Carcinoma - Gemcitabine - Palliative Chemotherapy
Schlüsselwörter
Gallenblasenkarzinom - Gemcitabine - palliative Chemotherapie
References
-
1
Duarte I, Llanos O, Domke H, Harz C, Valdivieso V.
Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples.
Cancer.
1993;
72
1878-1884
-
2
Silk Y N, Douglass H O, Nava H R, Driscoll D L, Tartarian G.
Carcinoma of the gallbladder.
Ann Surg.
1989;
210
751-757
-
3
Abi-Rached B, Neugut A I.
Diagnostic and management issues in gallbladder carcinoma.
Oncology.
1995;
9
19-24
-
4
Kopelson G, Harisiadis L, Tretter P, Chang C H.
The role of radiation therapy in cancer of the extra-hepatic biliary system: An analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy.
Int J Radiat Oncol Biol Phys.
1977;
2
883-894
-
5
Patt Y Z, Jones D V Jr, Hoque A. et al .
Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
J Clin Oncol.
1996;
14
2311-2315
-
6
Harvey J H, Smith F P, Schein P S.
5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
J Clin Oncol.
1984;
2
1245-1248
-
7
King R S.
Gemcitabine. New first-line therapy for pancreatic cancer.
Cancer Pract.
1996;
4
353-354
-
8
Zatloukal P, Kanitz E, Magyar P. et al .
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: The Central European phase II study.
Lung Cancer.
1998;
22
243-250
-
9
Lüftner D, Flath B, Akrivakis C. et al .
Gemcitabine for palliative treatment in metastatic breast cancer.
J Cancer Res Clin Oncol.
1998;
124
527-531
-
10
Aapro M S, Martin C, Hatty S.
Gemcitabine - a safety review.
Anticancer Drugs.
1998;
9
191-201
-
11
Raderer M, Hejna M H, Valencak J B. et al .
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Oncology.
1999;
56
177-180
-
12
Castro M P.
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: A case report.
Cancer.
1998;
82
639-641
-
13
Gallardo J, Fodor M, Gamargo C, Orlandi L.
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: A case report.
Cancer.
1998;
83
2419-2421
-
14
Metzger J, Sauerbruch T, Ko Y.
Phase II trial of gemcitabine in gallbladder and biliary tract carcinomas.
Onkologie.
1998;
21
232-234
-
15
Hamrick R E Jr, Liner F J, Hastings P R, Cohn I.
Primary carcinoma of the gallbladder.
Ann Surg.
1982;
195
270-273
Address for correspondence:
Priv.-Doz. Dr. med. Jochen Rudi
Medizinische Klinik IV Universitätsklinikum Heidelberg
Bergheimer Straße 58
69115 Heidelberg
eMail: jochen_rudi@med.uni-heidelberg.de
